Gossamer Bio Inc (GOSS)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Faheem Hasnain
Employees:
180
3013 SCIENCE PARK, SAN DIEGO, CA 92121
(858) 922-0718

Gossamer Bio, Inc. focuses on discovering, acquiring, developing, and commercializing therapeutics in immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor. GB5121, an oral, irreversible, covalent, small. molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central. central central nervous system lymphoma.

Data derived from most recent annual or quarterly report
Market Cap 175.139 Million Shares Outstanding76.48 Million Avg 30-day Volume 4.048 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-1.58
Price to Revenue0.0 Debt to Equity7.4355 EBITDA-205.011 Million
Price to Book Value21.8431 Operating Margin0.0 Enterprise Value611.325 Million
Current Ratio8.122 EPS Growth0.101 Quick Ratio7.858
1 Yr BETA 1.1323 52-week High/Low 15.2 / 1.57 Profit Margin0.0
Operating Cash Flow Growth-0.282 Altman Z-Score-4.0088 Free Cash Flow to Firm -142.59 Million
Earnings Report2023-03-02

Are you looking for this stock instead?

View SEC Filings from GOSS instead.

View recent insider trading info

Funds Holding GOSS (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding GOSS

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Events (8k)

  • 8-K: filed on 2022-12-06:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-03:
    Item 2.02: Results of Operations and Financial Condition
  • 8-K: filed on 2022-08-09:
    Item 2.02: Results of Operations and Financial Condition
  • 8-K: filed on 2022-07-13:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 3.02: Unregistered Sales of Equity Securities
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-10:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2022-05-10:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-04-25:
    Item 2.02: Results of Operations and Financial Condition
    Item 8.01: Other Events
  • 8-K: filed on 2022-03-03:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-11-08:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-10-12:
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • Prospectus

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    HASNAIN FAHEEM PRESIDENT & CEO

    • Officer
    • Director
    544,500 2022-12-07 3

    CHRISTIAN WAAGE EVP, TECH OPS AND ADMIN

    • Officer
    157,500 2022-12-07 3

    GIRAUDO BRYAN COO/CFO

    • Officer
    211,500 2022-12-07 3

    PETERSON CARYN EVP, REGULATORY AFFAIRS

    • Officer
    157,500 2022-12-07 3

    CARTER LAURA CHIEF SCIENTIFIC OFFICER

    • Officer
    157,500 2022-12-07 7

    ARANDA RICHARD CHIEF MEDICAL OFFICER

    • Officer
    157,500 2022-12-07 4

    COX RUSSELL J.

    • Director
    30,000 2022-06-09 1

    DANIEL THOMAS O

    • Director
    30,000 2022-06-09 1

    BUROW KRISTINA

    • Director
    30,000 2022-06-09 1

    GALA RENEE D

    • Director
    30,000 2022-06-09 1

    BILENKER JOSHUA H.

    • Director
    30,000 2022-06-09 1

    MILLIGAN SANDRA

    • Director
    30,000 2022-06-09 1

    SALTER-CID LUISA CHIEF SCIENTIFIC OFFICER

    • Officer
    206,065 2021-03-23 0

    DUPONT JAKOB CHIEF MEDICAL OFFICER

    • Officer
    46,500 2020-02-14 0

    GUJRATHI SHEILA PRESIDENT & CEO

    • Officer
    • Director
    4,237,742 2020-02-14 0

    OMEGA FUND V, L.P.

    OMEGA FUND V GP, L.P.

    OMEGA FUND V GP MANAGER, LTD.

    • 10% Owner
    No longer subject to file 2019-09-20 0

    OMEGA FUND V, L.P.

    OMEGA FUND V GP, L.P.

    OMEGA FUND V GP MANAGER, LTD.

    STAMPACCHIA OTELLO

    • 10% Owner
    • FORMER DIRECTOR.
    6,737,023 2019-09-16 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    HASNAIN FAHEEM - Director - Officer PRESIDENT & CEO

    2022-12-09 17:13:40 -0500 2022-12-07 A 544,500 a 544,500 direct

    GIRAUDO BRYAN - Officer COO/CFO

    2022-12-09 17:15:26 -0500 2022-12-07 A 211,500 a 211,500 direct

    CHRISTIAN WAAGE - Officer EVP, TECH OPS AND ADMIN

    2022-12-09 17:17:41 -0500 2022-12-07 A 157,500 a 157,500 direct

    ARANDA RICHARD - Officer CHIEF MEDICAL OFFICER

    2022-12-09 17:18:58 -0500 2022-12-07 A 157,500 a 157,500 direct

    PETERSON CARYN - Officer EVP, REGULATORY AFFAIRS

    2022-12-09 17:20:28 -0500 2022-12-07 A 157,500 a 157,500 direct

    CARTER LAURA - Officer CHIEF SCIENTIFIC OFFICER

    2022-12-09 17:21:46 -0500 2022-12-07 A 157,500 a 157,500 direct

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    GOSSAMER BIO INC GOSS 2023-01-26 22:15:03 UTC 3.241 1.079 85000
    GOSSAMER BIO INC GOSS 2023-01-26 21:45:03 UTC 3.241 1.079 85000
    GOSSAMER BIO INC GOSS 2023-01-26 21:15:04 UTC 3.241 1.079 85000
    GOSSAMER BIO INC GOSS 2023-01-26 20:45:03 UTC 3.241 1.079 85000
    GOSSAMER BIO INC GOSS 2023-01-26 20:15:04 UTC 3.241 1.079 85000
    GOSSAMER BIO INC GOSS 2023-01-26 19:45:03 UTC 3.241 1.079 85000
    GOSSAMER BIO INC GOSS 2023-01-26 19:15:04 UTC 3.241 1.079 85000
    GOSSAMER BIO INC GOSS 2023-01-26 18:45:03 UTC 3.241 1.079 85000
    GOSSAMER BIO INC GOSS 2023-01-26 18:15:04 UTC 3.241 1.079 85000
    GOSSAMER BIO INC GOSS 2023-01-26 17:45:04 UTC 3.241 1.079 85000
    GOSSAMER BIO INC GOSS 2023-01-26 17:15:04 UTC 3.241 1.079 85000
    GOSSAMER BIO INC GOSS 2023-01-26 16:45:03 UTC 3.2409 1.0791 85000
    GOSSAMER BIO INC GOSS 2023-01-26 16:15:04 UTC 3.2409 1.0791 85000
    GOSSAMER BIO INC GOSS 2023-01-26 15:45:03 UTC 3.2409 1.0791 85000
    GOSSAMER BIO INC GOSS 2023-01-26 15:15:04 UTC 3.2409 1.0791 85000
    GOSSAMER BIO INC GOSS 2023-01-26 14:45:04 UTC 3.242 1.078 85000
    GOSSAMER BIO INC GOSS 2023-01-26 14:15:03 UTC 3.242 1.078 85000
    GOSSAMER BIO INC GOSS 2023-01-26 13:45:03 UTC 3.242 1.078 85000
    GOSSAMER BIO INC GOSS 2023-01-26 13:15:04 UTC 3.242 1.078 85000
    GOSSAMER BIO INC GOSS 2023-01-26 12:45:04 UTC 3.242 1.078 85000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    FundVantage Trust- Gotham Enhanced Index Plus Fund GOSS -298.0 shares, $-3024.7 2020-03-31 N-PORT
    FundVantage Trust- Gotham Index Plus All-Cap Fund GOSS -278.0 shares, $-2821.7 2020-03-31 N-PORT
    Franklin Alternative Strategies Funds- Franklin K2 Alternative Strategies Fund GOSS -54310.0 shares, $-757624.5 2022-08-31 N-PORT
    JNL Series Trust- JNL Multi-Manager Alternative Fund GOSS -81465.0 shares, $-975950.7 2022-09-30 N-PORT
    FORUM FUNDS- ABSOLUTE CONVERTIBLE ARBITRAGE FUND GOSS -160100.0 shares, $-1917998.0 2022-09-30 N-PORT
    LAZARD FUNDS INC- Lazard Enhanced Opportunities Portfolio GOSS -24015.0 shares, $-287699.7 2022-09-30 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments